ReviewJournal of the American College of Cardiology2021
Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review.
Review in Journal of the American College of Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- SCMR expert consensus statement for cardiovascular magnetic resonance of patients with a cardiac implantable electronic device.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2024Guideline
- Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials.European journal of heart failure · 2022Pooled it
- Acute right-sided transcutaneous vagus nerve stimulation improves cardio-vagal baroreflex gain in patients with chronic heart failure.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025Trial
- Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.Circulation · 2022Trial
- Causal Inference Challenges in Evaluating Baroreflex Activation Therapy for Transthyretin Amyloid Cardiomyopathy: A Critical Appraisal.JACC. Case reports · 2026Article
- Pulmonary Embolism-Attributable Mortality in Patients With Heart Failure in the United States, 2010 to 2020.JACC. Advances · 2026Article
- Ablation of PKCα Phosphorylation by CRISPR-Cas9 Base Editing Rescues Heart Failure.Circulation research · 2026Article
- Cardiac Contractility Modulation (CCM) Therapy in Contemporary Heart Failure Care: Mechanisms, Evidence, Patient Selection, and Emerging Directions.Journal of clinical medicine · 2026Review
- Article
- Exosomes: bridge metabolic regulation in cardiac repair.npj biomedical innovations · 2025Review
- Device-therapy in chronic heart failure: Cardiac contractility modulation versus cardiac resynchronization therapy.ESC heart failure · 2025Observational
- Genetic polymorphisms inFrontiers in pharmacology · 2025Article
- Heart Failure Management in the Modern Era: A Comprehensive Review on Medical and Device-based Interventions.Current cardiology reviews · 2025Review
- The chronobiology of human heart failure: clinical implications and therapeutic opportunities.Heart failure reviews · 2025Review
- Identification and validation of key biomarkers of the glycolysis-ketone body metabolism in heart failure based on multi-omics and machine learning.Frontiers in cardiovascular medicine · 2025Article
- Role of Device Therapy in Complementing Contemporary Medical Management.US cardiology · 2025Review
- Novel device therapies in heart failure: focus on patient selection.Frontiers in cardiovascular medicine · 2025Review
- Early experience with baroreflex activation therapy from a vascular surgery perspective.Journal of vascular surgery cases and innovative techniques · 2024Article
- Future Training Pathways in Percutaneous Coronary Interventions: Interventional Critical Care, Complex Coronary Interventions, and Interventional Heart Failure.JACC. Advances · 2024Review
- Heart disease and heart failure: Trends and disparities in mortality rates in the United States from 2000 to 2020.American heart journal plus : cardiology research and practice · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 10 institutions in 4 countries.
Funding
Abstract
The regulatory landscape for device-based heart failure (HF) therapies has seen a major shift in the last 7 years. In 2013, the U.S. Food and Drug Administration released guidance for early feasibility and first-in-human studies, thereby encouraging device innovation, and in 2016 the U.S. Congress authorized the Breakthrough Devices Program to expedite access for Americans to innovative devices indicated for diagnosis and treatment of serious illnesses, such as HF. Since December 2016, there has been an increase in the number of HF devices for which manufacturers are seeking approval through the breakthrough designation pathway. This has led to a rapid uptake in the development and evaluation of device-based HF therapies. This article reviews the current and future landscape of device therapies for chronic HF and associated comorbidities and the regulatory environment that is driving current and future innovation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.